Cangrelor

Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y₁₂ inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.